Traws Pharma, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Traws Pharma, Inc. (TRAW) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -17.90% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-04-15
- Traws Pharma, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -17.90%.
- Traws Pharma, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -0.10%.
- Traws Pharma, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was 0.40%.
- Traws Pharma, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2020 was -0.20%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2024-12-31 | -17.90% 10-K · filed 2026-04-15 |
| 2023-12-31 | -0.10% 10-K · filed 2025-03-31 |
| 2021-12-31 | 0.40% 10-K · filed 2023-03-30 |
| 2020-12-31 | -0.20% 10-K · filed 2022-03-21 |
| 2019-12-31 | -0.10% 10-K · filed 2021-03-18 |
| 2018-12-31 | 1.40% 10-K · filed 2020-03-27 |
| 2017-12-31 | -8.10% 10-K · filed 2019-04-01 |
| 2016-12-31 | -5.90% 10-K · filed 2018-03-16 |
| 2015-12-31 | -13.60% 10-K · filed 2017-03-29 |
| 2014-12-31 | -8.90% 10-K · filed 2016-03-28 |
| 2013-12-31 | -8.30% 10-K · filed 2015-03-30 |
| 2012-12-31 | -25.10% 10-K · filed 2015-03-30 |
| 2011-12-31 | -5.60% 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |